Key result
Future management strategies for patients with heart failure with mildly reduced ejection fraction should focus on precision medicine and individualized care for optimized outcomes.
Why the study?
Direct, high-quality clinical evidence for HFmrEF remains limited due to inconsistent definitions and under-representation in major trials.
Answers are grounded in this paper and cite their sources.
Future management of HFmrEF should focus on precision medicine integrating advanced imaging, biomarker profiling, and genomics to optimize patient outcomes.
Heart failure with mildly reduced ejection fraction (HFmrEF) is increasingly recognized as a distinct yet heterogeneous phenotype within the heart failure spectrum. Advances in diagnostic tools, including strain imaging, cardiac magnetic resonance, and molecular imaging, together with progress in genomics and biomarker profiling, have contributed to a deeper understanding of the complex pathophysiology of HFmrEF. Although direct, high-quality clinical evidence remains limited due to inconsistent definitions and under-representation in major trials, recent studies and subgroup analyses have offered promising therapeutic options for HFmrEF patients. Given the significant heterogeneity of HFmrEF, future management strategies should focus on precision medicine and individualized care. Integrating advanced imaging, biomarker profiling, genomics, and phenotype-specific assessment will be essential for optimizing patient outcomes. Embracing this precision-based approach promises to redefine care pathways and improve prognosis for this under-recognized patient population.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question. Future management strategies for patients with heart failure with mildly reduced ejection fraction should focus on precision medicine and individualized care for optimized outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: